Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)

Background: The presence of T-lymphocytes in resected tumor samples derived from long-term survival patients and the fact that reinvigoration of their functionality through the administration of specific immune-therapies can lead to remarkable antitumor responses supports that lymphocytes play a critical role in cancer immunity. TIL-based ACT (Adoptive cell therapy using tumor-infiltrating lymphocytes product) is a modality of ACT used to treat patients with multiple types of cancer and it consists in the adoptive transfer of ex vivo expanded autologous tumor-infiltrating lymphocytes obtaine

Trial Details

NCT ID
NCT06630611
Phase
PHASE2
Sponsor
Vall d'Hebron Institute of Oncology
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • NMA-LD regimen
  • Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion
  • High dose IL-2
  • IL-2 analog
Locations (sample)
  • Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Patients must have histologically or cytologically proven metastatic or unresectable cutaneous melanoma, NSCLC, or cervical cancer. The disease mus…
  • Patients must have at least one adequate lesion (primary tumor or metastasis) for resection or biopsy (with minimal morbidity, preferentially using…
  • Note: If this lesion was previously irradiated, the lesion must have demonstrated progression prior to resection/biopsy.
  • Patients must have a remaining measurable disease as defined by RECIST v. 1.1 criteria following tumor resection/biopsy for TIL manufacturing.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →